



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN : L85195MP1988PLC004446

13th February, 2020

To,
Listing Department,
BSE Limited.
Rotunda Building, P J Towers
Dalal Street, Fort,
Mumbai – 400 001

To,
Listing Department,
National Stock Exchange of India Limited.
'Exchange Plaza', C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai – 400 051

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Reference: Scrip Code: ALPA ; ISIN: INE385I01010

Dear Sir/ Madam,

This is with reference to our letter dated 1st February, 2020 in relation to the intimation of board meeting; this is to inform you that the Board of Directors of the Company at its meeting held today at 4.00 p.m. at registered office of the Company situated at 33/2, A.B. Road Pigdamber Rao, Indore MP 453446 IN. The Board inter-alia has approved the following matter:

1. Approval of the Un-Audited Standalone & Consolidated Financial Results of the Company for Quarter ended on 31st December, 2019 with Limited Review Report from the Statutory Auditor of the Company.

This is for the information and record of the exchange and members thereof;

You are requested to take the same on records.

For ALPA LABORATORIES LIMITED

Mahendra Singh

Mahendra Singh Chawla
Director





**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON STANDALONE
QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF THE
SEBI LODR REGULATIONS, 2015**

To the Board of Directors of **ALPA LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **ALPA LABORATORIES LIMITED** for the quarter ended **December 31st, 2019**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For & on behalf of
ANURADHA RATNAPARKHI & ASSOCIATES.

Chartered Accountants

Firm Registration No.023451C


ANURADHA RATNAPARKHI

Proprietor

Membership Number: 075412

UDIN-20075412AAAAAA7984



Place: Indore

Date: 13th February, 2020

ALPA LABORATORIES LIMITED

Financial Results for Quarter and Nine Months ended on December 31st, 2019.

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE (M.P.)

(Rs. in lacs Except EPS)

Particular	Standalone Results					
	Quarter Ended			Nine Months Ended		Year Ended
	Dec-19	Sep-19	Dec-18	Dec-19	Dec-18	Mar-19
	Unaudited					Audited
1. Income						
a) Revenue from operations	2412.64	2351.28	2596.05	6,780.63	5889.38	7798.80
b) Other Income	116.41	35.33	61.55	219.68	268.47	506.52
Total income	2529.05	2386.60	2657.60	7,000.31	6157.86	8305.32
2. Expenses						
a) Cost of materials consumed	1,230.82	1,494.56	1,483.61	4,046.26	3,514.88	4,645.84
b) Purchases of stock-in-trade	20.75	44.21	20.23	115.16	58.40	84.66
c) Changes in inventories of finished products, work in progress and stock in trade	184.32	19.47	108.11	82.52	(18.95)	152.61
d) Employee benefit expenses	292.28	279.69	284.90	853.30	821.55	1204.10
e) Finance costs	2.81	4.49	10.38	16.26	49.97	56.87
f) Depreciation and amortization expense	28.68	27.26	29.31	81.03	85.26	109.57
g) Other expenses						
Manufacturing & Operating	105.04	116.30	112.32	320.17	314.42	425.85
Others	355.29	302.79	312.71	901.12	793.79	1185.37
Total expenses	2219.99	2288.77	2361.56	6,415.83	5619.32	7864.87
3. Profit/(Loss) before exceptional items and tax (1-2)	309.06	97.83	296.04	584.48	538.53	440.45
4. Exceptional Items	-	-	-	-	-	-
5. Profit/ Loss(-) before tax (3+/-4)	309.06	97.83	296.04	584.48	538.53	440.45
6. Tax (Expenses)/ Benefit						
Current tax	-	-	-	-	-	(108.13)
Deferred tax	-	-	-	-	-	(59.02)
Tax Related to Earlier Years	-	-	(2.01)	-	-	16.71
7. Profit/ Loss(-) for the period (5-/+6)	309.06	97.83	294.02	584.48	538.53	290.01
8. Other Comprehensive Income						
(i) (a) Items that will not be reclassified to profit or loss	0.50	0.30	-	2.18	-	(6.60)
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	0.50	0.30	-	2.18	-	(6.60)
9. Total comprehensive income for the period (7+8)	309.57	98.13	294.02	586.66	538.53	283.41
10. Paid-up equity share capital (Face Value Rs. 10 each)	2104.06	2104.06	2104.06	2,104.06	2104.06	2104.06
11. Other equity	-	-	-	-	-	8,486.87
12. Basic and Diluted Earnings per share after extraordinary items Rs. (not annualized)	1.47	0.47	1.40	2.79	2.56	1.35

Notes -

- The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Provision for Tax may not have been made for the partial/ unaudited periods.
- The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.

For ALPA LABORATORIES LIMITED
Mahendra
MAHENDRA SINGH CHAWLA
DIRECTOR
DIN NO.00362058



**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON CONSOLIDATED
QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF
THE SEBI LODR REGULATIONS, 2015**

To the Board of Directors of **ALPA LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **ALPA LABORATORIES LIMITED** for the quarter ended **December 31st, 2019**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial information issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For & on behalf of

ANURADHA RATNAPARKHI & ASSOCIATES.

Chartered Accountants

Firm Registration No.023451C

ANURADHA RATNAPARKHI

Proprietor

Membership Number: 075412

UDIN-20075412AAAAAB2537



Place: Indore

Date: 13th February, 2020

Particular	Consolidated Results					
	Quarter Ended		Nine Months Ended		Year Ended	
	Dec-19	Sep-19	Dec-18	Dec-19	Dec-18	Mar-19
	Unaudited					Audited
1. Income						
a) Revenue from operations	2412.64	2351.28	2596.05	6,780.63	5889.38	7798.80
b) Other Income	116.04	26.72	59.42	213.34	289.45	529.88
Total income	2528.68	2377.99	2655.48	6,993.97	6178.84	8328.68
2. Expenses						
a) Cost of materials consumed	1,230.82	1,494.56	1,483.61	4,046.26	3,514.88	4,645.84
b) Purchases of stock-in-trade	20.75	44.21	20.23	115.16	58.40	84.66
c) Changes in inventories of finished products, work in progress and stock in trade	184.32	19.47	108.11	82.52	(18.95)	152.61
d) Employee benefit expenses	292.28	279.69	284.90	853.30	821.55	1204.10
e) Finance costs	2.81	4.49	10.38	16.26	49.97	56.87
f) Depreciation and amortization expense	79.24	77.82	79.87	232.72	236.95	311.82
g) Other expenses						
Manufacturing & Operating	105.04	116.30	112.32	320.17	314.42	425.85
Others	355.45	302.81	312.72	909.71	794.05	1193.08
Total expenses	2270.71	2339.35	2412.13	6,576.11	5771.26	8074.83
3. Profit/(Loss) before exceptional items and tax (1-2)	257.97	38.65	243.34	417.86	407.57	253.85
4. Exceptional Items	-	-	-	-	-	-
5. Profit/ Loss(-) before tax (3+/-4)	257.97	38.65	243.34	417.86	407.57	253.85
6. Tax (Expenses)/ Benefit						
Current tax	-	-	-	-	-	(111.63)
Deferred tax	-	-	-	-	-	(59.02)
Tax Related to Earlier Years	-	-	(5.62)	-	(3.61)	9.56
7. Profit/ Loss(-) for the period (5-/+6)	257.97	38.65	237.72	417.86	403.97	92.76
8. Other Comprehensive Income						
(i) (a) Items that will not be reclassified to profit or loss	0.50	0.30	-	-	-	(6.60)
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	0.50	0.30	-	-	-	(6.60)
9. Total comprehensive income for the period (7+8)	258.48	38.95	237.72	417.86	403.97	86.16
10. Paid-up equity share capital (Face Value Rs. 10 each)	2104.06	2104.06	2104.06	2,104.06	2104.06	2104.06
11. Other equity	-	-	-	-	-	7,723.64
12. Basic and Diluted Earnings per share after extraordinary items Rs. (not annualized)	1.23	0.19	1.13	1.99	1.92	0.41

For ALPA LABORATORIES LIMITED
Mahendra
 MAHENDRA SINGH CHAWLA
 DIRECTOR
 DIN NO.00362058